The FibroScan mini 430 expanding access to the FibroScan technology. The most lightweight and portable option of the FibroScan family
Expand the reach of your
Using patented VCTE™ and CAP™ technologies, the FibroScan mini+ system is the latest and smallest addition to the FibroScan family of products.
Expanding innovation, the FibroScan mini+ offers mobility with the same experience and consistent results that you have come to expect from the FibroScan Compact systems.
Fibroscan mini+ ultra mobile design is ideal for multi-centers configuration and remote patients liver monitoring.
Fully compatible with FibroScan Gateway, allowing for improved patient management and efficiencies.
Touch screen data entry of 12.1 inches
Easy to transport – light weight: Approx 11lbs, Size: L=11″, x W=15.7″, x D= 3.7″
Plug in or Battery operated
Two probe connectors to easily switch between M+ and XL+ adult probes during the examination
Connectivity options: Multiple USB ports (export data, report to USB devices, exam report can be printed or exported on an external drive) to share information instantly
FibroScan® Gateway compatible
Available S+ probe for pediatric use
Indications for use
FibroScan Family of Products are indicated for noninvasive measurement in the liver of 50 Hz shear wave speed and estimates of stiffness as well as 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter).
The shear wave speed and stiffness, and CAP may be used as an aid to diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver.
Shear wave speed and stiffness may be used as an aid to clinical management of pediatric patients with liver disease.
Current media
FibroScan and Chronic Care Liver Disease Management
Self-Insured Employers Can Boost Workforce Productivity, Reduce Medical Costs Download our latest white paper: “Comprehensive Chronic Care Disease Management of Liver Disease Improves Member Outcomes, Reduces Costs for Employer-…
Read More
Economic Analysis Model Suggests Screening People for Fibrosis With Non-Invasive Tests Cost-effective
NASH Network (NASHNET), a global network of thought leaders dedicated to advancing care pathways for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), has published a novel cost-effectiveness analysis…
Read More
Echosens Cites Need for Liver Disease Monitoring for Medication Management of Psoriasis
Joint American Academy of Dermatology & National Psoriasis Foundation New Care Guidelines for Medication Management of Psoriasis Waltham, MA – August 12, 2020 – press release Echosens, a high-technology company…
Read More
Contact a representative
In North America there are over 1200+ FibroScan systems in operation & we’re growing!
